Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

ATTENTION MEMBERS:

Tonight, we're giving our website a serious makeover.

So if you can't access the site for a bit, don't worry, we're just sprucing things up for an even smoother experience.

In the event that you experience issues accessing the new site, please clear your browser's cookies and cache.

See You On The Other Side!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Follow

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

in response to

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

by

BearDownAZ

posted on Sep 28, 2022 04:22PM

Log in to use the IP Check tool ^[?]

So is this new trial replacing BETonMACE2, or are both trials still planned?

Maybe they are morphing BETonMACE2 into this new trial, with a focus on diabetic and/or CKD patients post-Covid?

And if this new trial is focusing on diabetic patients, are they planning on treating w/ just apabetalone or also with SGLT2 inhibitor, DPP4 inhibitor, or GLP1R-agonist (I can't remember off hand which drug combos showed synergy).

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions